Predict your next investment

Cumming company logo
Corporation
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing
ccorpusa.com

See what CB Insights has to offer

Founded Year

1996

Stage

Option/Warrant | Alive

Total Raised

$119.17M

Last Raised

$470K | 4 yrs ago

Revenue

$0000 

About Cumming

Cumming is an international project and cost management firm. Since opening for business in 1996, Cumming has provided efficient and cost-effective solutions to ensure that projects in the commercial, hospitality, retail, entertainment, education, healthcare and high-end residential sectors are executed on time and within budget. Cumming provides a solutions-oriented suite of services that specifically addresses its clients' unique challenges, thus enabling them to achieve extraordinary results.

Cumming Headquarter Location

523 W. 6th Street Suite 1001

Los Angeles, California, 90014,

United States

213-408-4518

Latest Cumming News

GeneThera Inc. Expands Its Operation In The United Kingdom

May 18, 2021

Expands Its Operation In The United Kingdom WESTMINSTER, Colo., May 18, 2021 (GLOBE NEWSWIRE) -- GeneThera is pleased to announce that it has incorporated a subsidiary in the United Kingdom. Author: May 18, 2021 7:00 AM EDT WESTMINSTER, Colo., May 18, 2021 (GLOBE NEWSWIRE) -- GeneThera is pleased to announce that it has incorporated a subsidiary in the United Kingdom. GeneThera Robotics Ltd, a majority owned subsidiary based in England, will be responsible for UK and International Operations. Mrs. Alex Baglietto has been appointed as Managing Director of GeneThera Robotics Limited. GeneThera Robotics is the first step of a global network of laboratories which will create the infrastructure of the Zoonotic Infectious Diseases Alert Shield (ZIDAS). ZIDAS, a network built on Molecular Robotic and AI technology (MORAP), is based on the development of two laboratory settings. The first, a stationary robotic lab facility designed for ultra-high throughput assay, genomic DNA sequencing and viral molecular therapeutics. The second, a mobile lab unit platform, designed to test wastewater for the presence of SARS-CoV-2 in communities worldwide. Dr. Tony Milici, Chairman and CEO of GeneThera Inc., commented: "We have decided to expand our operation to the UK because we see great opportunities both at the government and private sector level. The UK has been at forefront of the COVID-19 pandemic. The B.1.1.7 SARS CoV-2 British variant has proven to be of particular importance with an estimated transmission rate between forty to eighty percent more transmissible than the wild-type SARS-CoV-2 virus. Cases of B.1.1.7 variant are most likely to be under reported, if reported at all, as common tests are not able to differentiate this variant from other SARS-CoV-2 variants. We believe that our technology platform can significantly help in the detection of this variant by testing wastewater samples. Additionally, the appointment of Mrs. Baglietto, will prove to be a tremendous asset, as she has experience in business and government relations, communications, and in assisting clients in scaling-up business operations, and increasing inward investments." Mrs. Baglietto holds a B.A. and an M.A. from Cal State University at San Bernardino. She has worked both in the private and public sector and has experience dealing with government and business relations, clients, communications and investments. Mrs. Baglietto has worked with numerous private and public companies, most recently, assisting with assessing political risk, international trade investments and ministry of finance guarantees. Mrs. Baglietto stated, "I am extremely excited to be a part of such a promising and potentially life-saving company. I am aware of the challenges ahead and will utilize my strengths to propel the company forward. I have no doubt that similarly to COVID-19, humanity will continue to see the rise of other infectious diseases; GeneThera will be at the forefront of new COVID variants and other diseases. "GeneThera has likewise entered into a partnership agreement with Cumming Corporation, a privately held international consulting firm. Cumming Corporation will provide consulting support related to the building of laboratory facilities in the UK, as a part of GeneThera's ZIDAS global network strategy. About GeneThera, Inc.GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn's Disease in humans. We utilize these technologies to minimize the spread of animal infectious organisms such as SARS-CoV-2 to humans. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale.This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.For further information, please contact:Tony Milici MD, PhDGeneThera, Inc.(720) 587-5100 By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cumming Patents

Cumming has filed 4 patents.

The 3 most popular patent topics include:

  • Electrical generators
  • Engine components
  • Engine lubrication systems
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/30/2018

11/24/2020

Engine technology, Electrical generators, Engine lubrication systems, Engine components, Home appliances

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/30/2018

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/24/2020

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Engine technology, Electrical generators, Engine lubrication systems, Engine components, Home appliances

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Cumming Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cumming Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.